leptin peptide receptor antagonist 2

Leptin peptide receptor antagonist 2 (LPrA2) is a peptide-based antagonist of the leptin receptor (Ob-R / LEPR) developed by researchers at the Morehouse School of Medicine. It is designed based on the amino acid sequence 70–95 of human leptin binding site II. LPrA2 blocks leptin signaling, which is known to promote tumor cell proliferation, survival, angiogenesis, and chemoresistance, particularly in obesity-associated cancers. To improve its bioavailability and half-life, LPrA2 has been developed in pegylated (PEG-LPrA2) and iron oxide nanoparticle-conjugated (IONP-LPrA2) formulations. It has been investigated in preclinical models for the treatment of breast cancer (including triple-negative breast cancer, TNBC) and pancreatic cancer, where it has demonstrated the ability to inhibit tumor growth and enhance the efficacy of chemotherapeutic agents.

Other names

leptin peptide receptor antagonist 2pegylated leptin peptide receptor antagonist 2